Three years after discussing how to reuse an old scientific measuring device, Novartis scientists are now testing this idea as part of an innovative research project.

Compounds that block the production of damaging molecules might shed light on their role in disease—and lead to new therapies.

The cause of a rare, inherited, often fatal kidney disease in many patients remained elusive for years, despite multiple attempts to solve the mystery. Then in 2012, a team of researchers cracked some of the unsolved cases in just six weeks.

Making clinical tools from basic research knowledge is a practice Novartis and FMI researchers pursue. Read how they want to help retinitis pigmentosa patients to see the light.

Most people have never heard of spinal muscular atrophy (SMA), a rare genetic disease that affects approximately 1 in 6,000 babies born worldwide each year. Innovative research may produce treatments for patients suffering from SMA and other rare diseases.

Talk to any cancer researcher or doctor today and what you hear is wonder and hope.

Novartis is betting on both human inquisitiveness and computer expertise to harness the wealth of its digital research and development platform, data42.

Over the next 15 years chronic disease like cancer and heart disease will become major killers in Sub-Saharan Africa. A new report from the Economist Intelligence Unit explains why.

Chronic diseases kill 38 million people per year worldwide; almost three-quarters of those deaths occur in low- and middle-income countries. It’s time to act.